These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32267633)

  • 1. [A woman with a skin lesion suspected for melanoma].
    Post NF; Huis In 't Veld E; Crijns MB
    Ned Tijdschr Geneeskd; 2020 Feb; 164():. PubMed ID: 32267633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabrafenib plus trametinib in BRAF K601E-mutant melanoma.
    Rogiers A; Thomas D; Vander Borght S; van den Oord JJ; Bechter O; Dewaele M; Rambow F; Marine JC; Wolter P
    Br J Dermatol; 2019 Feb; 180(2):421-422. PubMed ID: 30248172
    [No Abstract]   [Full Text] [Related]  

  • 3. Sweet syndrome in metastatic melanoma during treatment with dabrafenib and trametinib.
    Scarfì F; Melotti B; Veronesi G; Ravaioli GM; Baraldi C; Lambertini M; Patrizi A; Dika E
    Australas J Dermatol; 2019 Aug; 60(3):e242-e243. PubMed ID: 30724336
    [No Abstract]   [Full Text] [Related]  

  • 4. Pomalidomide, dabrafenib mesylate, and trametinib dimethyl sulfoxide.
    Hussar DA; Kaminski JL
    J Am Pharm Assoc (2003); 2013; 53(5):550-8. PubMed ID: 24030134
    [No Abstract]   [Full Text] [Related]  

  • 5. Myasthenia gravis following dabrafenib and trametinib for metastatic melanoma.
    Zaloum A; Falet JR; Elkrief A; Chalk C
    Neurology; 2020 Feb; 94(7):322-323. PubMed ID: 31888971
    [No Abstract]   [Full Text] [Related]  

  • 6. Dabrafenib and trametinib combination therapy safely performed in a patient with metastatic melanoma after severe liver toxicity due to vemurafenib.
    Shimada S; Fukushima S; Niimori D; Miyashita A; Setoyama H; Sasaki Y; Ihn H
    J Dermatol; 2018 Jun; 45(6):e157-e158. PubMed ID: 29315749
    [No Abstract]   [Full Text] [Related]  

  • 7. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
    Dummer R; Hauschild A; Santinami M; Atkinson V; Mandalà M; Kirkwood JM; Chiarion Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Lesimple T; Plummer R; Dasgupta K; Gasal E; Tan M; Long GV; Schadendorf D
    N Engl J Med; 2020 Sep; 383(12):1139-1148. PubMed ID: 32877599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.
    Gerbasi ME; Stellato D; Ghate SR; Ndife B; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
    J Med Econ; 2019 Dec; 22(12):1243-1252. PubMed ID: 31223037
    [No Abstract]   [Full Text] [Related]  

  • 9. BRAF-mutated, acral verrucous melanoma successfully treated by dabrafenib plus trametinib combination therapy.
    Kiyohara T; Nagano N; Miyamoto M; Shijimaya T; Nakamaru S; Makimura K; Tanimura H
    Clin Exp Dermatol; 2019 Dec; 44(8):945-946. PubMed ID: 30950075
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
    Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM
    N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma.
    Hennemann A; Puzenat E; Decreuse M; Vuillier F; Nardin C; Aubin F
    Melanoma Res; 2024 Jun; 34(3):280-282. PubMed ID: 38602773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tattoo-associated complications of metastatic melanoma treated with dabrafenib and trametinib.
    Laske J; Meier F; Bauer A; Beissert S; Garzarolli M
    Melanoma Res; 2018 Oct; 28(5):485-487. PubMed ID: 30148769
    [No Abstract]   [Full Text] [Related]  

  • 14. Dabrafenib (Tafinlar) and trametinib (Mekinist) metastatic melanoma.
    Med Lett Drugs Ther; 2013 Aug; 55(1422):62-3. PubMed ID: 23917385
    [No Abstract]   [Full Text] [Related]  

  • 15. Discrepancy in responses to dabrafenib plus trametinib combination therapy in intracranial and extracranial metastases in melanoma patients.
    Kobayashi T; Matsumoto S; Shimizu K; Miyake M; Maeda S; Hamaguchi Y; Matsushita T
    J Dermatol; 2021 Feb; 48(2):e82-e83. PubMed ID: 33161591
    [No Abstract]   [Full Text] [Related]  

  • 16. Repeated complete response with long-term control of BRAF-mutant melanoma by multiple rechallenges with dabrafenib plus trametinib.
    Sasaki K; Nakamura Y; Baba N; Teramoto Y; Yamamoto A
    Eur J Cancer; 2020 Nov; 139():37-40. PubMed ID: 32957012
    [No Abstract]   [Full Text] [Related]  

  • 17. A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma.
    Marchand A; Tallet A; Collin C; Cormier B; Venel Y; Miquelestorena-Standley E; Machet L
    Br J Dermatol; 2018 Aug; 179(2):528-529. PubMed ID: 29494756
    [No Abstract]   [Full Text] [Related]  

  • 18. Evolution of melanocytic nevi under vemurafenib, followed by combination therapy with dabrafenib and trametinib for metastatic melanoma.
    Giurcaneanu C; Nitipir C; Popa LG; Forsea AM; Popescu I; Bumbacea RS
    Acta Dermatovenerol Croat; 2015; 23(2):114-21. PubMed ID: 26228819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective treatment with Dabrafenib and Trametinib for a BRAF-mutated metastatic dedifferentiated malignant spindle cell neoplasm.
    Escandell I; Cabezas M; Martín JM; Terradez L; Pinazo MI
    J Eur Acad Dermatol Venereol; 2016 Jul; 30(7):1224-6. PubMed ID: 25917403
    [No Abstract]   [Full Text] [Related]  

  • 20. Apparent darkening of scalp hair related to pili multigemini Following dabrafenib and trametinib.
    Avila C; Hoffman K; Milani-Nejad N; Pootrakul L
    Dermatol Online J; 2020 Jan; 26(1):. PubMed ID: 32155032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.